PGEN 8-K SEC Filing Analysis

Latest settled — T+5d

PGEN ▼ -6.96% at T+5d

LONG call ✗ call lost -6.96% · α vs SPY -6.24% · entry $4.60 → $4.28

Next anchor: T+20d tomorrow

Last close $3.57 (close Jun 8) · -22.39% from $4.60 entry

Entry anchored
May 13, 03:59 PM ET
via Databento tick

T+1d

0.00%

call 0.00% · α -0.01%

$4.60

settled 27d ago

T+5d

-6.96%

call -6.96% · α -6.24%

$4.28

settled 21d ago

T+20d

—

call — · α —

—

tomorrow

T+60d

—

call — · α —

—

in 8w

Price Chart

Loading chart...

Executive Summary

Precigen reported Q1 2026 revenue of $23.3M, massively up from $1.3M a year ago, driven by $21.6M in PAPZIMEOS product revenue in its first full commercial quarter. Net loss narrowed to $7.9M ($0.02/share) from $54.2M ($0.18/share) in Q1 2025, as the company transitions to a commercial-stage biopharma. The strong launch trajectory and cash position of $56.7M support management's expectation of reaching cash flow break-even by end of 2026.

Actionable Insight

The PAPZIMEOS launch is accelerating faster than expected, with Q1 revenue already exceeding the prior quarter's full-year total. The permanent J-code taking effect in April should further boost site activations and patient starts in Q2. Watch for continued revenue growth and progress toward cash flow break-even by year-end. The upcoming ASCO presentation (May 29-June 2) may provide additional catalyst on durability data.

Key Facts

Q1 2026 total revenue of $23.3M, up from $1.3M in Q1 2025, driven by $21.6M in PAPZIMEOS net product revenue
Net loss narrowed to $7.9M ($0.02/share) from $54.2M ($0.18/share) in Q1 2025
Cash, cash equivalents, and investments totaled $56.7M as of March 31, 2026
Approximately $25.7M in PAPZIMEOS-related accounts receivable not yet collected as of quarter-end
Company expects current cash plus anticipated PAPZIMEOS revenue to fund operations to cash flow break-even by end of 2026
Patient hub enrollment surpassed 400 patients, with 25% from community settings
Permanent J-code (J3404) effective April 1, 2026, expected to further streamline reimbursement and site activations

Financial Impact

Q1 2026 product revenue of $21.6M vs $0.2M in Q1 2025; net loss improved by $46.3M year-over-year

revenuenet losscash position

Risk Factors

Dependence on single product PAPZIMEOS for revenue; any commercial disruption would be material
Cash burn remains significant; break-even timeline depends on continued revenue acceleration
Long-term debt of $93.5M adds financial leverage and interest expense

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

78% bullish (9 analysts)

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0000950103-26-007158
Document: dp246650_8k.htm	0000950103-26-007158
Document: 0000950103-26-007158-index-headers.html	0000950103-26-007158
Document: 0000950103-26-007158-index.html	0000950103-26-007158
Document: 0000950103-26-007158.txt	0000950103-26-007158
8-K Data (Synthetic)	0000950103-26-007158

4 reports for PGEN

T+1T+5T+20T+60

Filters

Reports for PGEN — sortable, filterable
	Type				Now
Jun 1, 2026 8d ago	Insider Cluster NEUTRAL ★ 3/10	$3.86 $3.81	▼ −1.30%	▼ −0.60%	$3.57 (−7.51%)
Jun 1, 2026 8d ago	Insider Cluster NEUTRAL ★ 3/10	$3.86 $3.81	▼ −1.30%	▼ −0.57%	$3.57 (−7.51%)
May 13, 2026 27d ago	8-K BULLISH ★ 7/10	$4.60 $4.60	· 0.00%	▼ −0.01%	$3.57 (−22.39%)
Mar 30, 2026 10w ago	144 NEUTRAL ★ 3/10	$3.87 $3.93	▲ +1.55%	▲ +0.80%	$3.57 (−7.75%)

US Market Status

Market Closed — Opens in 8h 34m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access